Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study.
COVID-19
Multiple Sclerosis
Remote monitoring technologies
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
03
06
2020
accepted:
16
06
2020
pubmed:
4
7
2020
medline:
28
7
2020
entrez:
4
7
2020
Statut:
ppublish
Résumé
We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.
Identifiants
pubmed: 32617741
doi: 10.1007/s10072-020-04519-x
pii: 10.1007/s10072-020-04519-x
pmc: PMC7331489
doi:
Substances chimiques
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1647-1650Subventions
Organisme : Alzheimer's Society
ID : 171
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_17214
Pays : United Kingdom
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2012 Nov 24;380(9856):1819-28
pubmed: 23122652
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
JMIR Mhealth Uhealth. 2019 Aug 01;7(8):e11734
pubmed: 31373275
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264